ONDINE BIOMEDICAL INC. (OBI) — Results for the year ended 31 December 2025

Investor webinar replay

Replay transcript excerpt

Good afternoon, and welcome to the ONDINE BIOMEDICAL INvestor Presentation. Throughout this recorded presentation, investors will be in listen only mode. Questions are encouraged and they can be submitted at any time using the Q and A tab situated on the right hand corner of your screen. Just simply type in your questions and press send. Before we begin, I would like to submit the following poll. Today's presenters are Nicholas Lobel, President and Chief Technology Officer and Alan Thomas, CFO. I would now like to hand you over to Nicholas Lobel. Good afternoon to you. Thank you, Alex. Hello, and welcome to ONDINE's financial year twenty twenty five results presentation. Thank you for joining. My name is Nick Lobel, ONDINE's CTO and President. We will go through the presentation, which will be made available on our website, and we'll take questions after the presentation. This presentation provides general information. It's not intended to be a comprehensive analysis. Please review the company's annual report available today to investors. As a reminder, ONDINE is focused on blocking hospital acquired infections before they start, prior to and increasingly now after surgery. Remember, eight thousand surgeries are performed every day in The UK, one hundred and thirty thousand daily in The US. To address this challenge, ONDINE has developed a novel light activated antimicrobial called photodisinfection. This is a painless and broad spectrum approach. It's designed to rapidly eliminate microbes from various areas of the human body to prevent or even treat potentially devastating infections. For investors new to ONDINE, we're not an early stage research company. We have a proprietary technology platform. It's an active commercialization in Canada, The UK, and elsewhere. I...